This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced ... DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked to a reduced ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those taking DPP-4 drugs.